Neuroprotective effects of polysaccharides from wolfberry, the fruits of lycium barbarum, against homocysteine-induced toxicity in rat cortical neurons

Journal of Alzheimer's Disease

Volumn 19, Issue 3, 2010, Pages 813-827

  Ho, Yuen Shan ^a   Yu, Man Shan ^a   Yang, Xi Fei ^a   So, Kwok Fai ^a,b   Yuen, Wai Hung ^c   Chang, Raymond Chuen Chung ^a,b  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

^c UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Apoptosis; Homocysteine; Neuroprotection; Tau phosphorylation; Wolfberry

Indexed keywords

CASPASE 3; EPITOPE; GLYCOGEN SYNTHASE KINASE 3BETA; HOMOCYSTEINE; LACTATE DEHYDROGENASE; LYCIUM EXTRACT; MITOGEN ACTIVATED PROTEIN KINASE 3; POLYSACCHARIDE; STRESS ACTIVATED PROTEIN KINASE 1; TAU PROTEIN;

ANIMAL CELL; APOPTOSIS; ARTICLE; BRAIN CELL; CONTROLLED STUDY; CYTOTOXICITY; DOSE RESPONSE; EMBRYO; FRUIT; LYCIUM; NERVE CELL CULTURE; NERVE CELL LESION; NERVE CELL NECROSIS; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN PHOSPHORYLATION; RAT; WESTERN BLOTTING;

EID: 77149149070     PISSN: 13872877     EISSN: None     Source Type: Journal    
DOI: 10.3233/JAD-2010-1280     Document Type: Article

References (69)

1. Selhub J (1999) Homocysteine metabolism. Annu Rev Nutr 19, 217-246.
2. Jacques PF, Rosenberg IH, Rogers G, Selhub J, Bowman BA, Gunter EW, Wright JD, Johnson CL (1999) Serum total homocysteine concentrations in adolescent and adult Americans: results from the third National Health and Nutrition Examination Survey. Am J Clin Nutr 69, 482-489.
3. Selhub J, Jacques PF, Wilson PW, Rush D, Rosenberg IH (1993) Vitamin status and intake as primary determinants of homocysteinemia in an elderly population. JAMA 270, 2693-2698.
4. Hankey GJ, Eikelboom JW (2005) Homocysteine and stroke. Lancet 365, 194-196.
5. Bots ML, Launer LJ, Lindemans J, Hofman A, Grobbee DE (1997) Homocysteine, atherosclerosis and prevalent cardiovascular disease in the elderly: The Rotterdam Study. J Intern Med 242, 339-347. (Pubitemid 27475607)
6. Bots ML, Launer LJ, Lindemans J, Hoes AW, Hofman A,Witteman JC, Koudstaal PJ, Grobbee DE (1999) Homocysteine and short-term risk of myocardial infarction and stroke in the elderly: the Rotterdam Study. Arch Intern Med 159, 38-44. (Pubitemid 29044117)
7. Ravaglia G, Forti P, Maioli F, Martelli M, Servadei L, Brunetti N, Porcellini E, Licastro F (2005) Homocysteine and folate as risk factors for dementia and Alzheimer disease. Am J Clin Nutr 82, 636-643.
8. Seshadri S, Beiser A, Selhub J, Jacques PF, Rosenberg IH, D'Agostino RB, Wilson PW, Wolf PA (2002) Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. N Engl J Med 346, 476-483. (Pubitemid 34441738)
9. Clarke R, Smith AD, Jobst KA, Refsum H, Sutton L, Ueland PM (1998) Folate, vitamin B12, and serum total homocysteine levels in confirmed Alzheimer disease. Arch Neurol 55, 1449-1455.
10. McCaddon A, Davies G, Hudson P, Tandy S, Cattell H (1998) Total serum homocysteine in senile dementia of Alzheimer type. Int J Geriatr Psychiatry 13, 235-239.
11. Hassin-Baer S, Cohen O,Vakil E, Sela BA, Nitsan Z, Schwartz R, Chapman J, Tanne D (2006) Plasma homocysteine levels and Parkinson disease: disease progression, carotid intimamedia thickness and neuropsychiatric complications. Clin Neuropharmacol 29, 305-311.
12. O'Suilleabhain PE, Sung V, Hernandez C, Lacritz L, Dewey RB, Jr., Bottiglieri T, az-Arrastia R (2004) Elevated plasma homocysteine level in patients with Parkinson disease: motor, affective, and cognitive associations. Arch Neurol 61, 865-868.
13. Almeida OP, McCaul K, Hankey GJ, Norman P, Jamrozik K, Flicker L (2008) Homocysteine and depression in later life. Arch Gen Psychiatry 65, 1286-1294.
14. Dimopoulos N, Piperi C, Salonicioti A, Psarra V, Gazi F, Papadimitriou A, Lea RW, Kalofoutis A (2007) Correlation of folate, vitamin B12 and homocysteine plasma levels with depression in an elderly Greek population. Clin Biochem 40, 604-608.
15. Tiemeier H, van Tuijl HR, Hofman A, Meijer J, Kiliaan AJ, Breteler MM (2002) Vitamin B12, folate, and homocysteine in depression: the Rotterdam Study. Am J Psychiatry 159, 2099-2101.
16. Nakanishi T, Akabane ER, Nanami M, Kiyobayashi Y, Moriguchi R, Hasuike Y, Otaki Y, Miyagawa K, Itahana R, Izumi M (2005) Comparison of cytotoxicity of cysteine and homocysteine for renal epithelial cells. Nephron Exp Nephrol 100, e11-e20.
17. Jin L, Caldwell RB, Li-Masters T, Caldwell RW (2007) Homocysteine induces endothelial dysfunction via inhibition of arginine transport. J Physiol Pharmacol 58, 191-206.
18. Zieminska E, Lazarewicz JW (2006) Excitotoxic neuronal injury in chronic homocysteine neurotoxicity studied in vitro: the role of NMDA and group I metabotropic glutamate receptors. Acta Neurobiol Exp (Wars) 66, 301-309.
19. Saposnik G, Ray JG, Sheridan P, McQueen M, Lonn E (2009) Homocysteine-lowering therapy and stroke risk, severity, and disability: additional findings from the HOPE 2 trial. Stroke 40, 1365-1372.
20. Kim JH, Cho SY, Lee JH, Jeong SM, Yoon IS, Lee BH, Lee JH, Pyo MK, Lee SM, Chung JM, Kim S, Rhim H, Oh JW, Nah SY (2007)Neuroprotective effects of ginsenoside Rg3 against homocysteine-induced excitotoxicity in rat hippocampus. Brain Res 1136, 190-199.
21. Chan HC, Chang RCC, Ip KC, Chiu K, Yuen WH, Zee SY, So KF (2007) Neuroprotective effects of Lycium barbarum Lynn on protecting retinal ganglion cells in an ocular hypertension model of glaucoma. Exp Neurol 203, 269-273.
22. Chang RCC, So KF (2007) Use of Anti-aging Herbal Medicine, Lycium barbarum, Against Aging-associated Diseases. What Do We Know So Far? Cell Mol Neurobiol 28, 643-652.
23. Chao JC, Chiang SW,Wang CC, Tsai YH,Wu MS (2006) Hot water-extracted Lycium barbarum and Rehmannia glutinosa inhibit proliferation and induce apoptosis of hepatocellular carcinoma cells. World J Gastroenterol 12, 4478-4484.
24. Ho YS, Yu MS, Lai CS, So KF, Yuen WH, Chang RCC (2007) Characterizing the neuroprotective effects of alkaline extract of Lycium barbarum on beta-amyloid peptide neurotoxicity. Brain Res 1158C, 123-134.
25. Li XM (2007) Protective effect of Lycium barbarum polysaccharides on streptozotocin-induced oxidative stress in rats. Int J Biol Macromol 40, 461-465.
26. Yu MS, Lai CS, Ho YS, Zee SY, So KF,Yuen WH,Chang RCC (2007) Characterization of the effects of anti-aging medicine Fructus lycii on beta-amyloid peptide neurotoxicity. Int J Mol Med 20, 261-268.
27. Yu MS, Leung SK, Lai SW, Che CM, Zee SY, So KF, Yuen WH, Chang RCC (2005) Neuroprotective effects of anti-aging oriental medicine Lycium barbarum against beta-amyloid peptide neurotoxicity. Exp Gerontol 40, 716-727.
28. Chiu K, Chan HC, Yeung SC, Yuen WH, Zee SY, Chang RCC, So KF (2009) Modulation of microglia by Wolfberry on the survival of retinal ganglion cells in a rat ocular hypertension model. J Ocul Biol Dis Inform 2, 47-56
29. Ho YS, Yu MS, Yik SY, So KF, Yuen WH, Chang RCC (2009) Polysaccharides from Wolfberry antagonizes glutamate excitotoxicity in rat cortical neurons. Cell Mol Neurobiol, in press.
30. Seveg MG (1934) Deproteinization and removal of capsular polysaccharides. Biochem Z 273, 419-423
31. Chang RCC, Suen KC, Ma CH, Elyaman W, Ng HK, Hugon J (2002) Involvement of double-stranded RNA-dependent protein kinase and phosphorylation of eukaryotic initiation factor- 2alpha in neuronal degeneration. J Neurochem 83, 1215-1225.
32. Suen KC, Lin KF, Elyaman W, So KF, Chang RCC, Hugon J (2003) Reduction of calcium release from the endoplasmic reticulum could only provide partial neuroprotection against beta-amyloid peptide toxicity. J Neurochem 87, 1413-1426.
33. Yu MS, Ho YS, So KF, Yuen WH, Chang RCC (2006) Cytoprotective effects of Lycium barbarum against reducing stress on endoplasmic reticulum. Int J Mol Med 17, 1157-1161.
34. Lai SW, Yu MS, Yuen WH, Chang RCC (2006) Novel neuroprotective effects of the aqueous extracts from Verbena officinalis Linn. Neuropharmacology 50, 641-650.
35. LaiSW,Yu MS,Yuen WH, So KF, Zee SY, Chang RCC (2008) Antagonizing beta-amyloid peptide neurotoxicity of the antiaging fungus Ganoderma lucidum. Brain Res 1190, 215-224.
36. Chao J, Yu MS, Ho YS, Wang M, Chang RCC (2008) Dietary oxyresveratrol prevents parkinsonian mimetic 6- hydroxydopamine neurotoxicity. Free Radic Biol Med 45, 1019-1026.
37. Luo Y, Zhou X, Yang X, Wang JZ (2007) Homocysteine induces tau hyperphosphorylation in rats. Neuroreport 18, 2005-2008.
38. Kruman II, Culmsee C, Chan SL, Kruman Y, Guo Z, Penix L, Mattson MP (2000) Homocysteine elicits a DNA damage response in neurons that promotes apoptosis and hypersensitivity to excitotoxicity. J Neurosci 20, 6920-6926.
39. Boldyrev AA, Johnson P (2007) Homocysteine and its derivatives as possible modulators of neuronal and non-neuronal cell glutamate receptors in Alzheimer's disease. J Alzheimers Dis 11, 219-228.
40. Zhang CE, Tian Q,WeiW, Peng JH, Liu GP, Zhou XW,Wang Q, Wang DW, Wang JZ (2007) Homocysteine induces tau phosphorylation by inactivating protein phosphatase 2A in rat hippocampus. Neurobiol Aging 29, 1654-1665.
41. Sontag E, Nunbhakdi-Craig V, Sontag JM, az-Arrastia R, Ogris E, Dayal S, Lentz,S.R, Arning,E, Bottiglieri,T (2007) Protein phosphatase 2A methyltransferase links homocysteine metabolism with tau and amyloid precursor protein regulation. J Neurosci 27, 2751-2759.
42. Quintanilla RA, Matthews-Roberson TA, Dolan PJ, Johnson GV (2009) Caspase-cleaved tau expression induces mitochondrial dysfunction in cortical neurons: implications for the pathogenesis of Alzheimer's disease. J Biol Chem 284, 18754-18766.
43. Rissman RA, Poon WW, Blurton-Jones M, Oddo S, Torp R, VitekMP, LaFerla FM, RohnTT, CotmanCW(2004) Caspasecleavage of tau is an early event in Alzheimer disease tangle pathology. J Clin Invest 114, 121-130.
44. Wang JZ, Liu F (2008) Microtubule-associated protein tau in development, degeneration and protection of neurons. Prog Neurobiol 85, 148-175.
45. Goedert M, Hasegawa M, Jakes R, Lawler S, Cuenda A, Cohen P (1997) Phosphorylation of microtubule-associated protein tau by stress-activated protein kinases. FEBS Lett 409, 57-62.
46. Reynolds CH, Utton MA, Gibb GM, Yates A, Anderton BH (1997) Stress-activated protein kinase/c-jun N-terminal kinase phosphorylates tau protein. J Neurochem 68, 1736-1744.
47. Reynolds CH, Betts JC, Blackstock WP, Nebreda AR, Anderton BH (2000) Phosphorylation sites on tau identified by nanoelectrospray mass spectrometry: differences in vitro between the mitogen-activated protein kinases ERK2, c-Jun Nterminal kinase and P38, and glycogen synthase kinase-3beta. J Neurochem 74, 1587-1595.
48. Pacheco-Quinto J, Rodriguez de Turco EB, DeRosa S,Howard A, Cruz-Sanchez F, Sambamurti K, Refolo L, Petanceska S (2006) Hyperhomocysteinemic Alzheimer's mouse model of amyloidosis shows increased brain amyloid beta peptide levels. Neurobiol Dis 22, 651-656.
49. Zhang CE, Wei W, Liu YH, Peng JH, Tian Q, Liu GP, Zhang Y, Wang JZ (2009) Hyperhomocysteinemia increases betaamyloid by enhancing expression of gamma-secretase and phosphorylation of amyloid precursor protein in rat brain. Am J Pathol 174, 1481-1491.
50. Ho PI, Ortiz D, Rogers E, Shea TB (2002) Multiple aspects of homocysteine neurotoxicity: glutamate excitotoxicity, kinase hyperactivation and DNA damage. J Neurosci Res 70, 694-702.
51. Kruman II, Kumaravel TS, Lohani A, Pedersen WA, Cutler RG, Kruman Y, Haughey N, Lee J, Evans M, Mattson MP (2002) Folic acid deficiency and homocysteine impair DNA repair in hippocampal neurons and sensitize them to amyloid toxicity in experimental models of Alzheimer's disease. J Neurosci 22, 1752-1762.
52. Perry IJ, Refsum H, Morris RW, Ebrahim SB, Ueland PM, Shaper AG (1995) Prospective study of serum total homocysteine concentration and risk of stroke in middle-aged British men. Lancet 346, 1395-1398.
53. Verhoef P, Hennekens CH, Malinow MR, Kok FJ,Willett WC, Stampfer MJ (1994) A prospective study of plasma homocyst( e)ine and risk of ischemic stroke. Stroke 25, 1924-1930.
54. Nurk E, Refsum H, Tell GS, Engedal K, Vollset SE, Ueland PM, Nygaard HA, Smith AD (2005) Plasma total homocysteine and memory in the elderly: the Hordaland Homocysteine Study. Ann Neurol 58, 847-857.
55. Quadri P, Fragiacomo C, Pezzati R, Zanda E, Tettamanti M, Lucca U (2005) Homocysteine and B vitamins in mild cognitive impairment and dementia. Clin Chem Lab Med 43, 1096-1100. (Pubitemid 41581967)
56. Aisen PS, Schneider LS, Sano M, az-Arrastia R, van Dyck CH, Weiner MF, Bottiglieri T, Jin S, Stokes KT, Thomas RG, Thal LJ (2008) High-dose B vitamin supplementation and cognitive decline in Alzheimer disease: a randomized controlled trial. JAMA 300, 1774-1783.
57. Viswanathan A, Raj S, Greenberg SM, Stampfer M, Campbell S, Hyman BT, Irizarry MC (2009) Plasma Abeta, homocysteine, and cognition: the Vitamin Intervention for Stroke Prevention (VISP) trial. Neurology 72, 268-272.
58. Obeid R, Herrmann W (2006) Mechanisms of homocysteine neurotoxicity in neurodegenerative diseases with special reference to dementia. FEBS Lett 580, 2994-3005.
59. Lipton SA, Kim WK, Choi YB, Kumar S, D'Emilia DM, Rayudu PV, Arnelle DR, Stamler JS (1997) Neurotoxicity associated with dual actions of homocysteine at the N-methyl- D-aspartate receptor. Proc Natl Acad Sci USA 94, 5923-5928.
60. Jara-Prado A, Ortega-Vazquez A, Martinez-Ruano L, Rios C, Santamaria A (2003) Homocysteine-induced brain lipid peroxidation: effects of NMDAreceptor blockade, antioxidant treatment, and nitric oxide synthase inhibition. Neurotox Res 5, 237-243.
61. Baydas G, Reiter RJ, Akbulut M, Tuzcu M, Tamer S (2005) Melatonin inhibits neural apoptosis induced by homocysteine in hippocampus of rats via inhibition of cytochrome c translocation and caspase-3 activation and by regulating pro- and anti-apoptotic protein levels. Neuroscience 135, 879-886.
62. Perna AF, Ingrosso D, De Santo NG (2003) Homocysteine and oxidative stress. Amino Acids 25, 409-417.
63. Khatoon S, Grundke-Iqbal I, Iqbal K (1994) Levels of normal and abnormally phosphorylated tau in different cellular and regional compartments of Alzheimer disease and control brains. FEBS Lett 351, 80-84.
64. Vafai SB, Stock JB (2002) Protein phosphatase 2A methylation: a link between elevated plasma homocysteine and Alzheimer's Disease. FEBS Lett 518, 1-4.
65. Guillozet-Bongaarts AL, Garcia-Sierra F, Reynolds MR, Horowitz PM, Fu Y, Wang T, Cahill ME, Bigio EH, Berry RW, Binder LI (2005) Tau truncation during neurofibrillary tangle evolution in Alzheimer's disease. Neurobiol Aging 26, 1015-1022.
66. Chung CW, Song YH, Kim IK, Yoon WJ, Ryu BR, Jo DG, Woo HN, Kwon YK, Kim HH, Gwag BJ, Mook-Jung IH, Jung YK (2001) Proapoptotic effects of tau cleavage product generated by caspase-3. Neurobiol Dis 8, 162-172.
67. Sahara N, Murayama M, Lee B, Park JM, Lagalwar S, Binder LI, Takashima A (2008) Active c-jun N-terminal kinase induces caspase cleavage of tau and additional phosphorylation by GSK-3beta is required for tau aggregation. Eur J Neurosci 27, 2897-2906.
68. Leveugle B, Ding W, Laurence F, Dehouck MP, Scanameo A, Cecchelli R, Fillit H (1998) Heparin oligosaccharides that pass the blood-brain barrier inhibit beta-amyloid precursor protein secretion and heparin binding to beta-amyloid peptide. J Neurochem 70, 736-744.
69. Sakurai-Yamashita Y, Kinugawa H, Niwa M (2006) Neuroprotective effect of pentosan polysulphate on ischemia-related neuronal death of the hippocampus. Neurosci Lett 409, 30-34.